587,854 Abbott Laboratories $ABT Shares Acquired by Sepio Capital LP

Key Points

• Sepio Capital LP increased its Abbott Laboratories stake by 296.5% in the third quarter, acquiring 587,854 shares and bringing its total holdings to 786,102 shares worth approximately $77.7 million.
• Abbott reported quarterly earnings of $1.42 per share and revenue of $13.01 billion, with sales up 14.5% year over year. The company also declared a quarterly dividend of $0.63 per share, equivalent to a 2.5% annual yield.
• Analysts maintain a generally bullish view, with a consensus “Moderate Buy” rating and an average price target of $118.32, although several firms lowered targets amid a reduced sales-growth outlook and weakness in some medical-device businesses.

Sepio Capital LP raised its position in Abbott Laboratories (NYSE:ABT - Free Report) by 296.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 786,102 shares of the healthcare product maker's stock after buying an additional 587,854 shares during the quarter. Abbott Laboratories comprises about 3.1% of Sepio Capital LP's holdings, making the stock its 7th largest position. Sepio Capital LP's holdings in Abbott Laboratories were worth $77,691,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Manning & Napier Advisors LLC purchased a new stake in Abbott Laboratories in the 2nd quarter worth about $31,000. Summit Securities Group LLC lifted its holdings in Abbott Laboratories by 41.3% during the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker's stock valued at $37,000 after purchasing an additional 118 shares during the last quarter. Addison Advisors LLC purchased a new stake in Abbott Laboratories during the second quarter valued at about $40,000. Hoey Investments Inc. boosted its position in Abbott Laboratories by 59.3% during the first quarter. Hoey Investments Inc. now owns 446 shares of the healthcare product maker's stock worth $46,000 after purchasing an additional 166 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. boosted its position in Abbott Laboratories by 221.6% during the second quarter. E Fund Management Hong Kong Co. Ltd. now owns 476 shares of the healthcare product maker's stock worth $43,000 after purchasing an additional 328 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Up 2.1%

Shares of ABT opened at $102.64 on Friday. The company has a market capitalization of $177.61 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 1.86 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The stock has a fifty day simple moving average of $105.30 and a two-hundred day simple moving average of $98.28. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting the consensus estimate of $1.42. The company had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The firm's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.30 earnings per share. As a group, equities analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories's dividend payout ratio is 81.55%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ABT shares. Robert W. Baird lifted their target price on shares of Abbott Laboratories from $121.00 to $123.00 and gave the stock an "outperform" rating in a research note on Thursday. JPMorgan Chase & Co. dropped their price target on shares of Abbott Laboratories from $120.00 to $118.00 and set an "overweight" rating on the stock in a research note on Thursday. UBS Group dropped their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. BTIG Research cut their price objective on shares of Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating for the company in a report on Thursday. Finally, Weiss Ratings raised Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, September 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $118.32.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted EPS of $1.42, in line with the main consensus estimate, and revenue of $13.01 billion, slightly above the $12.99 billion estimate. Reported sales rose 14.5% year over year, while comparable sales increased 7%. Abbott third-quarter results
• Positive Sentiment: Abbott reaffirmed its full-year adjusted EPS guidance, and analysts continue to see upside. Wells Fargo raised its price target to $119, while Robert W. Baird raised its target to $123. Citigroup, RBC, JPMorgan, TD Cowen and BTIG lowered targets but retained bullish ratings, including “buy,” “outperform” or “overweight.”
• Positive Sentiment: The company received European approval for its Cologuard Plus colorectal-cancer screening test, expanding the potential market for its diagnostics portfolio. Abbott Cologuard Plus European approval
• Neutral Sentiment: Abbott plans a tax-free separation of its approximately $8.5 billion Nutrition business into an independent, publicly traded company by the end of 2027. Management says the move could give both businesses more focused investment strategies, but investors face execution, allocation and valuation uncertainty during the transition. Abbott Nutrition separation announcement
• Negative Sentiment: Abbott reduced its 2026 sales-growth outlook, citing pressure from diabetes-related pricing and weakness in parts of its electrophysiology and medical-device businesses. This softer outlook overshadowed the quarterly revenue performance and led several analysts to trim price targets. Abbott lowers 2026 sales forecast
• Negative Sentiment: India’s food regulator issued a notice involving infant-formula claims related to Nestlé India and Abbott, creating a limited regulatory overhang for Abbott’s Nutrition operations. India infant-formula regulatory notice

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.